Hereditary Transthyretin Amyloidosis (hATTR) Competitive Landscape and Market Insights

Aug 14, 2020

10 likes | 22 Views

In 2017 the Familial Amyloid Polyneuropathy (FAP) patient in the United States was found to be 2,588 while Italy and France had 612 and 512 FAP patients respectively. With a growth rate of 10.2% Hereditary Transthyretin Amyloidosis (hATTR) has the highest diagnosed prevalence in the United States while Japan has the lowest number which is expected to grow at a CAGR of 9.9% over the forecast period. The market size of Hereditary Transthyretin Amyloidosis (hATTR) in the 7MM was USD 306.9 Million in 2017. Recent approvals of effective treatment, diverse pathophysiology, increased awareness, increasing healthcare expenditure and improved reimbursement policies are some of the key factors expected to drive the httr market forward in the coming years. The key players in the Hereditary Transthyretin Amyloidosis (hATTR) market includes Alnylam Pharmaceuticals, Eidos Therapeutics, Ionis Pharmaceuticals and many others. For more details on hrrt market visit: https://www.delveinsight.com/report-store/hereditary-transthyretin-amyloidosis-competitive-landscape-and-market

DelveInsight

Download Presentation

Hereditary Transthyretin Amyloidosis (hATTR) Competitive Landscape and Market Insights

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D